ROYAL CANIN® is part of the Royal Canin Division in the Mars, Incorporated group, and a global leader in Health Through Nutrition for cats and dogs fulfilling its Purpose: A BETTER WORLD FOR PETS. Founded in 1968 by French veterinarian, Dr. Jean Cathary, ROYAL CANIN® designs precise, science-based nutrition for cats and dogs available at pet specialty retailers and veterinary practices worldwide.
Over the years, ROYAL CANIN® has pushed the limits of nutrition and knowledge in partnership with pet professionals, including breeders and veterinarians. Its unique business approach puts the nutritional requirements of cats and dogs at the heart of innovation. Pet’s age, lifestyle, size, breed, and sensitivities are studied through science and observation to produce diets that meet their specific needs.
ROYAL CANIN® generates value not only for pets, but also for people and the planet. This means being mutually beneficial to the ecosystem, empowering Associates, building enduring relationships with stakeholders, and always thinking about how to ensure a viable future for generations to come.
Shenzhen Mindray Animal Medical Technology Co., LTD. (short as Mindray Animal Medical), as a new wholly-owned subsidiary of Mindray Group, is dedicated to providing advanced medical devices and comprehensive solutions for animals, including companion animals, farm animals, equine, and exotic animals.
We are committed to offering equal access to high-quality healthcare by meeting different demands of veterinarians to care for a wide variety of animals.
With a broad portfolio of products covering medical imaging systems, patient monitoring & life support, and In-Vitro diagnostics of animals, we're improving the healthcare experience for animals and enhancing confidence for animal caregivers.
Zoetis, Inc., formerly the animal health business unit of Pfizer Inc., is now an independent global leader in animal health. We have accumulated more than 70 years of experience and have more than 1,600 scientists around the world dedicated to pharmaceutical development, with global sales of $8.5 billion in 2023, making us the only animal health company to be listed in the U.S. Fortune 500.
Zoetis’ product portfolio covers animal vaccines, parasiticides, antibiotics, diagnostic reagents, anti-emetic medicine, anesthesia and sedation, anti-itch drugs, therapeutic monoclonal antibodies, etc. In May 2018, Zoetis invested 2 billion US dollars to complete the acquisition of Abaxis, the world's top listed diagnostic medical company, took the lead in becoming the first animal health company to be able to provide "diagnosis - prevention - treatment" multi-faceted solutions; Since 2019, Zoetis had acquired a number of famous reference laboratories in the United States (including Phoenix, ZNLabs and Ethos), and in 2022 invested in the establishment of a third-party testing laboratory in Beijing and Shanghai in China, greatly enriching the scope of diagnostic services.
Adhering to the spirit of scientific research and innovation, Zoetis officially launched the world's first veterinary JAK inhibitor Apoquel® in 2013, the world’s first monoclonal antibody Cytopoint® for canine atopic dermatitis in 2016, followed by the launch of the first monoclonal antibody Librela® for canine with osteoarthritis pain, the first monoclonal antibody Solensia® for feline with osteoarthritis pain, new generation parasiticide of isooxazoline Revolution Plus® and Simparica Trio® from 2019 to 2021, leading veterinary medicine into a new era.
At the Purina Institute, we transform nutrition science into actionable information that you can put into practice to benefit your patients. And through the Purina Institute’s extensive online resources, publications and scientific programs, you can stay armed with the unbiased, science-based nutrition information you need to help pets live better, longer lives.
To learn more, visit PurinaInstitute.com and follow us on social media.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Boehringer Ingelheim entered Chinese market in 1994, with its headquarters in Shanghai. It operates nationwide and currently has about 3,700 employees across the country. Boehringer Ingelheim China focuses on Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing with full value chain footprint including R&D, manufacturing, commercial operation and external innovation collaboration. China is a focus market and source of innovation for Boehringer Ingelheim. China’s needs have been incorporated into the company’s global R&D strategy. The company aims to bring more and better innovative products earlier to the Chinese patients, contribute to the high-quality development of China’s healthcare industry, and comprehensively improve the health of human and animals. In recent years, the company has achieved continuous development, and has been certified as “China Top Employer” for eleven consecutive years. For more information, please visit: www.boehringer-ingelheim.cn, www.boehringer-ingelheim.com
